What is the recommended HPV vaccination schedule by age?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

HPV Vaccination Schedule by Age

Routine HPV vaccination should be administered at age 11-12 years using a 2-dose schedule (0,6-12 months apart) for all children who initiate vaccination before their 15th birthday. 1

Age-Based Dosing Algorithm

Ages 9-14 Years

  • 2-dose schedule (0,6-12 months)
  • Can start as early as age 9 years
  • The second dose must be administered at least 6 months after the first dose 1, 2
  • If the first dose is given at age 14 years, only one additional dose is needed >6 months later to complete the series, regardless of when that second dose is actually given 1

Key rationale: Younger children (ages 9-14) demonstrate higher geometric mean antibody titers compared to 16-26 year-olds, providing robust immune responses with fewer doses 1. The immune response with a 12-month interval is more robust than a 6-month interval 1.

Ages 15-26 Years

  • 3-dose schedule (0,1-2,6 months) 2, 3
  • Applies to anyone initiating vaccination on or after their 15th birthday
  • Catch-up vaccination is recommended for all persons through age 26 who are not adequately vaccinated 3, 4

Ages 27-45 Years

  • Shared clinical decision-making is recommended (not routine catch-up) 3, 4
  • 3-dose schedule if vaccination is pursued
  • HPV vaccines are not licensed for use in adults >45 years 3

The evidence shows that vaccine effectiveness decreases with age due to prior HPV exposure—effectiveness is 74-93% in ages 9-14 but declines significantly in older populations 5. Most sexually active adults have already been exposed to some HPV types, reducing potential benefit 3.

Special Populations

Immunocompromised Individuals

  • 3-dose schedule regardless of age at initiation 2, 3
  • This includes HIV-infected individuals, even if immunocompetent 6

Pregnancy and Lactation

  • HPV vaccination should be delayed until after pregnancy 4
  • Pregnancy testing is not required before vaccination
  • Persons who are breastfeeding can receive HPV vaccine 4

Critical Implementation Points

Timing is paramount: The rationale for targeting ages 11-12 is based on epidemiologic data showing nearly 40% cumulative HPV infection within 2 years after first sexual intercourse, and 24% of adolescents report sexual activity by 9th grade 1. Vaccination must occur before sexual debut for maximum effectiveness.

No prevaccination testing: Do not perform Pap testing or HPV DNA testing to determine appropriateness of vaccination 3, 4. History of genital warts, abnormal Pap tests, or positive HPV DNA does not preclude vaccination 7, 8.

Vaccine type: As of January 2017, only the 9-valent HPV vaccine (9vHPV) is available in the United States, protecting against HPV types 6,11,16,18,31,33,45,52, and 58 1. This vaccine is 97% effective against cervical, vulvar, and vaginal cancer precursor lesions related to the additional five types 1.

Series completion: A series begun with quadrivalent vaccine can be completed with 9vHPV 1. The critical determinant for number of doses needed is the age at first dose, not the age at subsequent doses 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.